<DOC>
	<DOCNO>NCT02760758</DOCNO>
	<brief_summary>This First Human study orally administer CDI-31244 , non-nucleoside inhibitor ( NNI ) healthy volunteer HCV infect individual</brief_summary>
	<brief_title>A Study CDI-31244 : A Novel NNI HV HCV Infected Subjects</brief_title>
	<detailed_description>This single center , double-blind , placebo-controlled , randomize , single ascend oral dose multiple oral dose design , incorporate fed/fasted comparison . The study include two group : Group A - single ascend dose ( SAD ) include food effect cohort , multiple dose ( MD ) healthy volunteer ( HV ) , Group B MD Hepatitis C Virus ( HCV ) infect individual divide two part . Five single-dose cohort plan . For five single-dose cohort , sentinel group 2 subject dose least one day prior enrol remain subject . Six multiple-dose cohort plan . Three multiple dose cohort healthy volunteer three cohort HCV-infected individual . The dose Group B conduct follow safety pharmacokinetic ( PK ) review Group A . The dose Group B , Part 2 conduct Part 1 show acceptable safety efficacy result .</detailed_description>
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Main HV HCV INFECTED SUBJECTS : Male female age ≥ 18 ≤ 65 year ; Body mass index ≥ 18.5 ≤ 35.0 kg/m2 ; Body weight ≥ 50 kg ; Negative screen alcohol drug abuse ; Normal result 12lead electrocardiogram ( ECG ) ; For female , negative result pregnancy test . HCV INFECTED SUBJECTS : HCV treatmentnaïve subject must receive prior direct act agent ( DAA ) treatment hepatitis C infection ; Documented clinical history compatible chronic hepatitis C ; HCV Genotype 1 HCV genotyping perform Screening ; Plasma HCV RNA ≥ 5.0 log10 IU/mL Screening ; Laboratory evidence cirrhosis ( negative liver biopsy fibroscan FibroTest , F2 low ) within one year prior study ) , available , FibroTest screening , must F2 low . Main HV HCV INFECTED SUBJECTS : Females pregnant lactate ; Coinfected hepatitis B virus ( HBV , HBsAg positive ) and/or human immunodeficiency virus ( HIV ) ; Abuse alcohol and/or drug could interfere adherence study requirement judge investigator ; Positive screen result drug abuse alcohol Day 1 . Use investigational drug within 60 day dose ; Subject intestinal malabsorption ; Presence outofrange cardiac interval screen ECG clinically significant ECG abnormality ; Serum creatinine &gt; upper limit normal ( ULN ) ; Any clinically significant medical condition , opinion investigator , would jeopardize safety subject impact validity study result . HEALTHY VOLUNTEERS : Positive screen antiHCV antibody HCV INFECTED SUBJECTS : Clinical ( opinion investigator ) laboratory evidence cirrhosis ; History sign decompensated liver disease : ascites , variceal bleeding , hepatic encephalopathy , spontaneous bacterial peritonitis , clinical sign portal hypertension hepatic insufficiency ; History hepatocellular carcinoma ( HCC ) finding suggestive possible HCC ; Active clinically significant disease .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>non-nucleoside inhibitor</keyword>
	<keyword>NNI</keyword>
	<keyword>HCV</keyword>
	<keyword>DAA</keyword>
</DOC>